Lovastatin Inhibits Phenylephrine-Induced ERK Activation and Growth of Cardiac Myocytes

• Published in: Cardiovascular toxicology Vol. 1; no. 3; pp. 237 - 252
• Main Authors: Melchert, Russell B, Liu, Hui, Granberry, Mark C, Kennedy, Richard H
• Format: Journal Article
• Language: English
• Published: Totowa Springer Nature B.V 2001
• Subjects: Cells; Rodents
• ISSN: 1530-7905; 1530-7905; 1559-0259
• DOI: 10.1385/CT:1:3:237

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) exert numerous cellular effects through the inhibition of cholesterol synthesis. The objectives of these experiments were to determine the following: (1) whether lovastatin (LOV) inhibits phenylephrine (PE)-induced growth of neonatal rat cardiac myocytes without inducing cytotoxicity and (2) whether growth-inhibiting effects of LOV are associated with reduced PE activation of extracellular signal regulated kinases 1 and 2 (ERK 1/2). After 48 h of exposure, LOV alone (0.1-10 μM) inhibited 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction without significant changes in propidium iodide staining, and 100 μM mevalonic acid prevented the effect of LOV on MTT reduction. PE (50 or 100-μM for 48 h) induced significant increases in protein-to-DNA ratios. PE (100 μM for 5 min) significantly increased the phosphorylated forms of ERK 1 and ERK 2 and activity of ERK. After 24 h pretreatment or 48 h cotreatment, LOV (10 μM) significantly inhibited PE-induced growth. In addition, LOV pretreatment significantly inhibited the stimulatory effect of PE on ERK 2 phosphorylation and ERK activity. These results demonstrate that LOV, at concentrations that do not alter membrane integrity, inhibits PE-induced growth of cardiac myocytes, potentially through reduced activation of ERK 1/2.[PUBLICATION ABSTRACT]